Miragen Therapeutics, Inc. (MGEN) financial statements (2021 and earlier)

Company profile

Business Address 6200 LOOKOUT ROAD
BOULDER, CO 80301
State of Incorp. DE
Fiscal Year End December 31
SIC 8071 - Medical Laboratories (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:27344451627176
Cash and cash equivalents 252418333243
Short-term investments292033303933
Other undisclosed cash, cash equivalents, and short-term investments25(0)(0)(0)   
Receivables0100011
Other undisclosed current assets3343344
Total current assets:30384854657681
Noncurrent Assets
Property, plant and equipment1111111
Other noncurrent assets  00000
Total noncurrent assets:1111111
TOTAL ASSETS:30394955667782
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6654464
Accounts payable1211110
Accrued liabilities5543444
Debt4443210
Total current liabilities:101097774
Noncurrent Liabilities
Long-term debt and lease obligation45678910
Long-term debt, excluding current maturities45678910
Liabilities, other than long-term debt  00000
Other liabilities  00000
Total noncurrent liabilities:45678910
Total liabilities:15161514151614
Stockholders' equity
Stockholders' equity attributable to parent16233341516168
Common stock0000000
Additional paid in capital184181180179177176174
Accumulated other comprehensive income (loss) 000(0)(0)0
Accumulated deficit(168)(158)(147)(138)(126)(116)(107)
Total stockholders' equity:16233341516168
TOTAL LIABILITIES AND EQUITY:30394955667782

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:1130012
Operating expenses(11)(12)(11)(12)(11)(10)(11)
Operating loss:(10)(11)(9)(12)(10)(9)(9)
Nonoperating income0000000
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Net loss available to common stockholders, diluted:(10)(11)(9)(12)(10)(9)(9)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(10)(11)(9)(12)(10)(9)(9)
Comprehensive loss:(10)(11)(9)(12)(10)(9)(9)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)000(0)0
Comprehensive loss, net of tax, attributable to parent:(10)(11)(9)(12)(10)(9)(9)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: